Brainmarker-I differentially predicts remission to various attention-deficit/hyperactivity disorder treatments: a blinded discovery, transfer and validation study

CONCLUSION: The present study introduces a clinically interpretable and actionable biomarker based on the iAPF assessed during resting-state electroencephalography. Our findings suggest that acknowledging neurobiological heterogeneity can inform stratification of patients to their individual best treatment and enhance remission rates.

via https://pubmed.ncbi.nlm.nih.gov/35240343/?utm_source=no_user_agent&utm_medium=rss&utm_campaign=None&utm_content=1L37KAMf2b_g4WEK3LmdFuKZu9pO3cN7u4ZmO9PPCPeBLMIw1q&fc=None&ff=20220326020902&v=2.17.6